2. Search Result
Search Result
Results for "

SIRT1-IN-3

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-174806
    Y040-7904

    7-(β-D-Galactopyranosyloxy)-4-phenylchromen-2-one

    		 Mitophagy PINK1/Parkin Amyloid-β Neurological Disease
    Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β (Aβ) accumulation in both in vitro and in vivo models of Alzheimer’s disease.
    Y040-7904
  • HY-124113
    4'-Bromo-resveratrol

    4′‐BR

    		 Sirtuin Apoptosis Caspase Lactate Dehydrogenase GLUT Metabolic Disease Inflammation/Immunology Cancer
    4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD +/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .
    4'-Bromo-resveratrol
  • HY-16616
    SIRT-IN-2

    		Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 nM, respectively.
    SIRT-IN-2
  • HY-103636
    PROTAC Sirt2 Degrader-1
    1 Publications Verification

    		 Sirtuin PROTACs Cancer
    PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM) .
    PROTAC Sirt2 Degrader-1
  • HY-146690
    SIRT1-IN-3

    		Sirtuin Cancer
    SIRT1-IN-3 (compound 3j) is a potent and selective SIRT1 inhibitor, with an IC50 of 4.2 μM .
    SIRT1-IN-3
  • HY-16615
    SIRT-IN-1
    1 Publications Verification

    		 Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 nM, respectively.
    SIRT-IN-1
  • HY-133998
    SIRT-IN-3
    1 Publications Verification

    		 Sirtuin Cancer
    SIRT-IN-3 is a potent SIRT inhibitor, with an IC50 of 17 μM for SIRT1. SIRT-IN-3 shows about 4-fold and 14-fold selectivity for SIRT1 over SIRT2 and SIRT3, respectively (IC50 of 74 μM and 235 μM for SIRT2 and SIRT3, respectively) .
    SIRT-IN-3
  • HY-111317
    SIRT1 activator 3

    		Sirtuin Metabolic Disease
    SIRT1 activator 3 is a potent activator of Sirt1 and suppresses TNF-α in a dose-dependent manner. SIRT1 activator 3 has the potential for anti-obesity or anti-diabetic researches .
    SIRT1 activator 3
  • HY-168020
    SJ-106C

    		Sirtuin Mitochondrial Metabolism Cancer
    SJ-106C is a SIRT inhibitor, with IC50 values of 0.59, 0.12, and 0.49 μM for SIRT1/2/3 respectively. SJ-106C can target mitochondria and inhibit the growth of DLBCL tumors .
    SJ-106C
  • HY-W109401
    SIRT-IN-6

    		Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with IC50 values of >50 μM. SIRT-IN-6 is promising for research of metabolic, inflammatory, oncologic and neurodegenerative disorders .
    SIRT-IN-6
  • HY-114906
    SIRT1/2/3-IN-2

    		Sirtuin Cancer
    SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma .
    SIRT1/2/3-IN-2
  • HY-155729
    Sirt1/2-IN-4

    		Sirtuin Apoptosis Cancer
    Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC50s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity .
    Sirt1/2-IN-4
  • HY-103636R
    PROTAC Sirt2 Degrader-1 (Standard)

    		Reference Standards Sirtuin PROTACs Cancer
    PROTAC Sirt2 Degrader-1 (Standard) is the analytical standard of PROTAC Sirt2 Degrader-1 (HY-103636). This product is intended for research and analytical applications. PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM) .
    PROTAC Sirt2 Degrader-1 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: